Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
37,911,631
-
Share change
-
-183,488
-
Total reported value
-
$431,767,392
-
Put/Call ratio
-
25%
-
Price per share
-
$11.39
-
Number of holders
-
125
-
Value change
-
-$15,478,031
-
Number of buys
-
54
-
Number of sells
-
63
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2018
As of 31 Dec 2018,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
125 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,911,631 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., Vanguard Group Inc, BB BIOTECH AG, WASATCH ADVISORS INC, DIMENSIONAL FUND ADVISORS LP, SAMLYN CAPITAL, LLC, SCHRODER INVESTMENT MANAGEMENT GROUP, CITADEL ADVISORS LLC, and STATE STREET CORP.
This page lists
125
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.